3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
3
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
18
Carcinoma, Non-Small-Cell Lung
10
Carcinoma, Renal Cell
9
Kidney Neoplasms
4
Stomach Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Hepatocellular
3
Skin Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Various Advanced Cancer
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms
1
Melanoma, Cutaneous Malignant
1
Lymphatic Metastasis
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
Ipilimumab
×
Clear all
NCT03937219
2025-09-10
COSMIC-313
Exelixis
Phase 3
Active not recruiting
855 enrolled
12 charts